brief summary：Materials and methodsPatientsA total of 402 consecutive patients with stage III coloncancer who underwent primary tumor resection betweenNovember 2007 and June 2016 at Sun Yat-sen Univer

This study included 402 patients with stage III colon cancer who underwent primary tumor resection and adjuvant chemotherapy with the XELOX regimen. The patients were followed up for at least 3 months after chemotherapy. The tumor specimens were analyzed for lymphovascular invasion (LVI) and perineural invasion (PNI) status. The patients were monitored for disease-free survival (DFS) and overall survival (OS). Statistical analyses were performed to identify independent risk factors for survival outcomes